TY - JOUR AU - Lamim Lovatel, Viviane AU - Otero, Luize AU - Orlando, Ercole Pietro AU - Diniz, Claudia AU - dos Santos-Bueno, Filipe Vicente AU - Almeida Lopes, Bruno AU - Almeida Antônio de Kós, Elaiza AU - Kopischitz Praxedes Lusis, Monica AU - Abdelhay, Eliana AU - Fernandez, Teresa de Souza PY - 2022/01/01 Y2 - 2024/03/28 TI - Clinical and Prognostic Features in a Young Adult Patient with de novo Myelodysplastic Syndrome presenting t(11;16) (q23; q24) JF - Mediterranean Journal of Hematology and Infectious Diseases JA - Mediterr J Hematol Infect Dis VL - 14 IS - 1 SE - Letters to the Editor DO - 10.4084/MJHID.2022.013 UR - https://www.mjhid.org/mjhid/article/view/4789 SP - e2022013 AB - <p>hematopoietic clonal neoplasms. MDS occurs mainly in elderly patients. <em>KMT2A</em> rearrangements (<em>KMT2A</em>-r) are rare in MDS, so little is known about their prognostic value. The present study describes the clinical characteristics of a young adult patient diagnosed with MDS-EB-2, presenting the t(11;16)(q23;q24). The Decitabine treatment was initiated since no matching donor was found. The patient showed improved anemia and thrombocytopenia. However, he still had severe neutropenia and clonal chromosomal alteration. &nbsp; Two months after the fifth cycle of Decitabine, the patient presented a worsening of the clinical parameters with increased blast and evolution to AML. He was treated with intensification chemotherapy, but despite all efforts, the patient evolved to death. Treatment refractoriness and leukemia transformation suggest that t(11;16)(q23;q24) with <em>KMT2A</em>-r was associated with poor prognosis. This study reinforces the importance of characterizing new chromosomal alterations and their impact on prognosis in MDS.</p> ER -